Page last updated: 2024-09-03

safinamide and Dyskinesia, Drug-Induced

safinamide has been researched along with Dyskinesia, Drug-Induced in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S1
Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M1
Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J1
Deeks, ED1

Reviews

2 review(s) available for safinamide and Dyskinesia, Drug-Induced

ArticleYear
▼ Safinamide for Parkinson's disease.
    Drug and therapeutics bulletin, 2018, Volume: 56, Issue:5

    Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2018
Safinamide: first global approval.
    Drugs, 2015, Volume: 75, Issue:6

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Cognition Disorders; Drug Approval; Dyskinesia, Drug-Induced; Humans; Internationality; Parkinson Disease

2015

Trials

1 trial(s) available for safinamide and Dyskinesia, Drug-Induced

ArticleYear
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:10

    Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome

2014

Other Studies

2 other study(ies) available for safinamide and Dyskinesia, Drug-Induced

ArticleYear
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:3

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction

2018
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:5

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome

2013